Tereza Pavlištová

Nov 22, 2024 | bioprocessintl.com | Xiaojun Liu |Brian Gazaille |Allan Bream |Tereza Pavlištová

Gene therapies are emerging as promising treatments for previously untreatable genetic disorders, with adeno-associated viruses (AAVs) being the preferred vector for gene delivery. However, AAV-based gene therapies face challenges in production, including cost, complexity, and scalability. With the gene therapy market projected to grow significantly, drug developers are seeking platforms that streamline AAV production.